Actually, we know much about management of AF in symptomatic patients. However, many patients with AF are asymptomatic. Silent AF is far more frequent than symptomatic AF in patients with paroxysmal AF. Moreover, both clinical and silent AF, are associated with an increased risk of thromboembolism. With advancement in technology and widespread use of cardiac devices, subclinical atrial tachyarrhythmias (AT) are becoming more visible. Although device-detected subclinical ATs are frequently encountered in daily practice, management of them is not addressed by current guidelines. Physicians need expert recommendations to guide management of these tachyarrhythmias.
European Heart Rhythm Association, recently published a consensus document that address clinical management of device-detected subclinical AT with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) (1) . We provide here the key messages from document conceptualized by specialist dealing with such problems in daily practice.
Consensus document firstly reviews the detection properties of cardiac devices. It underlines the advantage of cardiac electronic devices to detect subclinical atrial fibrillation (SCAF). Patients with cardiac implanted electronic devices (CIEDs) have an advantage over patients who do not have implanted device because clinically silent arrhythmias can be detected. In addition, remote monitoring can also provide earlier detection compared to standard scheduled follow-up.
Besides these advantages, even in automatic detection of AF by devices, false positive and false negative detections may lead to misinterpretation of stored data. Therefore, consensus document recommends the implantation of a bipolar atrial lead for reliable AF detection if it is indicated. High atrial sensitivity is also crucial to avoid intermittent undersensing of AF. Most importantly, review of stored intracardiac electrograms to confirm diagnosis and exclude artifact or reduce the effect of oversensing/undersensing by automated algorithms is recommended by the document.
In high-risk patients who have no CIEDs, noninvasive monitoring may be considered for detection of SCAF. The 24-hour Holter monitor is the most established but least sensitive device for continuous ECG monitoring. Other devices with longer monitoring periods (e.g. longer term Holter monitoring and event recorders) are associated with a greater rate of SCAF detection. However, the cost of the methods is also increasing.
Implantable loop recorders (ILR) are invasive systems that provide very long monitoring period. Continuous arrhythmia monitoring up to 1-year in patients with cryptogenic stroke detects AF with prevalence of 20% (2). However, the topography (shape, size and location) of the cerebral ischemic infarction area is not related to AF prevalence (3). Although they can be used for AF detection after cryptogenic stroke, this strategy has not been shown to have clinical utility in regard to future stroke prevention (4). In the consensus report, it is stated that implantation of ILR may be limited in patients with cryptogenic stroke other than clinical research subjects. The need of comparative studies on these various external devices and cost-effectiveness analyses on the use of these devices is also reported. Inexpensive and noninvasive tools like smartphone ECG applications are offered for screening of SCAFs, especially in patients with ischemic stroke or TIA without a history of AF.
After review of detection methods, uncertainties in pathophysiologic link between device detected AT and thromboembolic risk is discussed.
All major studies regarding the thromboembolic risk of SCAF in patients with CIEDs show significant increases in stroke rate associated with device-detected atrial high rate episodes (AHRE) (5-11). However, the minimum duration of episode or AT/AF burden (longest total duration of AF on any given day), which confers increased thromboembolic risk is not precisely defined. The minimum duration of device-detected AF that increases thromboembolic risk is not certain, it may be as brief as 5 minutes to several hours.
Temporal association between AHREs and the occurrence of stroke is also not clear. Related studies revealed unexpected findings; there was no AF on the device recordings in the majority of patients (73-94%) in the 30 days prior to the thromboembolic events (4, (11) (12) (13) . These findings suggest that the mechanism of stroke may not be related to the AF episodes. AHRE could simply be a risk marker for stroke, or reflect an indirect mechanism related to multiple comorbidities associated with stroke.
Consensus document cites the recent studies focusing on fibrotic atrial cardiomyopathy and thromboembolism have led to a new paradigm of understanding the mechanism of stroke. AF may not be a direct causal, but it may be marker and an amplifier of underlying atrial pathology (14, 15) .
The authors also remind the risk of excessive supraventricular ectopic activity (ESVEA) associated with risk of incident AF, stroke and mortality (16, 17) . They note that excessive supraventricular ectopic activities documented by Holter monitoring can be considered be a surrogate marker for paroxysmal AF.
At the end of the document authors, make valuable recommendations for daily practice, especially for oral anticoagulation therapy. First, they emphasize that the symptoms are not decisive instruments determining the need for anticoagulation.
For patients with two additional CHA 2 DS 2 -VASc risk factors (ie. ≥2 in males, ≥3 in females) oral anticoagulation is recommended for AF burden >5.5 h/day. Nevertheless, it should be kept in mind that the minimum duration of AHRE that increases thromboembolic risk is not certain. Therefore, lower duration may merit oral anticoagulation if multiple risk factors are present. At the same time, it is reasonable to follow-up a patient with only a single 5-min episode to observe their AF burden over time before committing them to life-long oral anticoagulation.
Consensus document suggest to consider oral anticoagulation for AF burden of >5.5 h in patients with one additional CHA 2 DS 2 -VASc risk factor and not to start antithrombotic therapy for any patient with CHA 2 DS 2 -VASc score of 0 irrespective of AHRE.
This well-prepared document comprehensively reviews the pathophysiologic link between device-detected SCAF and stroke. It answers many daily clinical questions for management of SCAF and treatment with oral anticoagulation.
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